Bicycle Therapeutics plc (NASDAQ: BCYC) to Post 2021 Third Quarter Earnings of ($ 0.79) per Share, Expected by B. Riley
Bicycle Therapeutics plc (NASDAQ: BCYC) – B. Riley stock analysts released their earnings per share estimates for the third quarter of 2021 for Bicycle Therapeutics in a research report released to customers and investors on Thursday, September 30. B. Riley analyst K. Patel expects the company to post earnings per share of ($ 0.79) for the quarter. B. Riley has a “Buy” rating and a target price of $ 56.00 on the stock. B. Riley also released Bicycle Therapeutics earnings estimates for the fourth quarter of 2021 at ($ 0.89) EPS, FY2021 EPS at $ 3.16, FY2022 EPS at 4.20 $, EPS for fiscal 2023 at $ 5.41 EPS, EPS for fiscal 2024 at $ 7.25 for EPS and earnings for fiscal 2025 at ($ 7.20) EPS.
A number of other research analysts have also weighed in on BCYC recently. Canaccord Genuity increased its target price on Bicycle Therapeutics from $ 30.00 to $ 36.00 and gave the stock a “buy” rating in a report released on Tuesday, July 13. JMP Securities reaffirmed a “buy” note and issued a price target of $ 53.00 on shares of Bicycle Therapeutics in a research note on Wednesday, August 11. Piper Sandler raised her price target on Bicycle Therapeutics from $ 39.00 to $ 46.00 and rated the stock “overweight” in a research note on Tuesday, July 13. Finally, Zacks Investment Research downgraded Bicycle Therapeutics from a “buy” rating to a “hold” rating in a Friday August 6 research note. One equity research analyst rated the stock with a conservation rating and seven gave the company a buy rating. According to data from MarketBeat.com, Bicycle Therapeutics currently has a consensus rating of “Buy” and an average target price of $ 45.88.
BCYC stock opened at $ 44.52 on Monday. Bicycle Therapeutics has a fifty-two week low of $ 17.68 and a fifty-two week high of $ 45.21. The company’s 50-day average mobile price is $ 35.88, and its two-hundred-day average mobile price is $ 32.27. The company has a debt ratio of 0.21, a rapid ratio of 9.36 and a current ratio of 9.36. The company has a market cap of $ 1.14 billion, a price-to-earnings ratio of -15.79 and a beta of -0.34. Bicycle Therapeutics (NASDAQ: BCYC) last released its results on Thursday, August 5. The company reported ($ 0.74) earnings per share for the quarter, missing analyst consensus estimates of ($ 0.71) by ($ 0.03). Bicycle Therapeutics recorded a negative return on equity of 50.43% and a negative net margin of 546.62%. The company posted revenue of $ 1.79 million for the quarter, compared to $ 2.51 million expected by analysts.
Separately, insider Nigel Crockett sold 72,701 shares in a trade on Tuesday, July 13. The stock was sold at an average price of $ 32.44, for a total trade of $ 2,358,420.44. As a result of the transaction, the insider now directly owns 4,331 shares of the company, valued at approximately $ 140,497.64. The transaction has been disclosed in a legal file with the Securities & Exchange Commission, which is available through this link. Additionally, CFO Lee Kalowski sold 12,500 shares in a trade on Thursday, July 29. The shares were sold for an average price of $ 31.51, for a total value of $ 393,875.00. Following the transaction, the Chief Financial Officer now directly owns 12,500 shares of the company, valued at $ 393,875. Disclosure of this sale can be found here. During the last quarter, insiders sold 136,447 shares of the company valued at $ 4,536,400. Company insiders own 17.90% of the company’s shares.
A number of institutional investors have recently changed their positions in the stock. Point72 Asset Management LP increased its stake in Bicycle Therapeutics by 14.5% in the 2nd quarter. Point72 Asset Management LP now owns 1,805,935 shares of the company valued at $ 54,828,000 after purchasing an additional 228,442 shares during the period. Janus Henderson Group PLC purchased a new position in Bicycle Therapeutics in the 1st quarter valued at $ 50,654,000. Logos Global Management LP purchased a new position in Bicycle Therapeutics in the 1st quarter valued at $ 23,896,000. FIL Ltd purchased a new position in Bicycle Therapeutics in the 1st quarter valued at $ 15,628,000. Finally, Verition Fund Management LLC increased its stake in Bicycle Therapeutics by 609.7% during the first quarter. Verition Fund Management LLC now owns 240,134 shares of the company valued at $ 7,173,000 after acquiring an additional 206,300 shares during the period. 48.67% of the shares are currently held by institutional investors.
About cycling therapy
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company engaged in the development of a new class of drugs, which the company calls bicycles, for diseases underserved by existing therapies. The company uses its new proprietary phage display screening platform to identify bicycles.
See also: Operating result
This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Bicycle Therapeutics now?
Before you consider Bicycle Therapeutics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the larger market takes hold of… and Bicycle Therapeutics was not on the list.
Although Bicycle Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here